Cover art for ALX Oncology Q3 2026 Results

ALX Oncology Q3 2026 Results

ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance.

3 cards · 40s · tap to begin

From · · · 40s

ALX Oncology Q3 2026 Results

ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance.

In brief

ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance. ALX Oncology Holdings Inc. reported a narrower net loss of $0.15 per share in Q3 2026, down 63.4% from Q3 2025. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.

Q3 2026 Financial Results

ALX Oncology Holdings Inc. reported a narrower loss for the third quarter of 2026.

Net Loss Details

The company posted a net loss of $21.8M for the quarter, translating to a loss of $0.15 per share.

Improvement from Previous Year

Improvement from Previous Year

The $0.15 per share loss narrowed 63.4% from the $0.41 loss ALX Oncology recorded in the third quarter of 2025.

What to remember

ALX Oncology Holdings Inc. reported a narrower net loss of $0.15 per share in Q3 2026, down 63.4% from Q3 2025.

Read the original on Alphastreet - Earnings Decoded. Market Intelligence Delivered

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on alx oncology holdings inc and related topics.